1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107
2. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6): 2403–2413. doi:10.1200/JCO.1997.15.6.2403
3. Conroy T, Desseigne F, Ychou M, Bouch e O, Guimbaud R, B ecouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19): 1817–1825. doi:10.1056/NEJMoa1011923
4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:10.1056/ NEJMoa1304369
5. Moses AW, Slater C, Preston T, Barber MD, Fearon KC. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer. 2004;90(5):996–1002. doi:10.1038/sj.bjc.6601620
6. Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, Gouma DJ, Giacosa A, Van Gossum A, Bauer J, Barber MD, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003;52(10):1479–1486. doi:10.1136/gut.52.10.1479
7. Fearon KC, Barber MD, Moses AG. The cancer cachexia syndrome. Surg Oncol Clin N Am. 2001;10(1):109–126.
8. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105. doi:10.1038/nrdp.2017.105
9. Evans WK, Nixon DW, Daly JM, Ellenberg SS, Gardner L, Wolfe E, Shepherd FA, Feld R, Gralla R, Fine S, et al. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-smallcell lung cancer. J Clin Oncol. 1987;5(1):113–124. doi:
10.1200/JCO.1987.5.1.113 10. Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol. 1993; 11(10):2043–2049. doi:10.1200/JCO.1993.11.10.2043
11. Beck SA, Smith KL, Tisdale MJ. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res. 1991;51(22): 6089–6093.
12. Murphy RA, Mourtzakis M, Chu QSC, Baracos VE, Reiman T, Mazurak VC. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer. 2011; 117(16):3774–3780. doi:10.1002/cncr.25933
13. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985;69(12): 1375–1381.
14. Caillet P, Liuu E, Raynaud Simon A, Bonnefoy M, Guerin O, Berrut G, Lesourd B, Jeandel C, Ferry M, Rolland Y, et al. Association between cachexia, chemotherapy and outcomes in older cancer patients: a systematic review. Clin Nutr. 2017;36(6):1473–1482. doi:10.1016/j.clnu.2016.12.003
15. Punzi T, Fabris A, Morucci G, Biagioni P, Gulisano M, Ruggiero M, Pacini S. C-reactive protein levels and vitamin d receptor polymorphisms as markers in predicting cachectic syndrome in cancer patients. Mol Diagn Ther. 2012;16(2):115–124. doi: 10.2165/ 11632380-000000000-00000.
16. Baumgartner RN, Koehler KM, Romero L, Garry PJ. Serum albumin is associated with skeletal muscle in elderly men and women. Am J Clin Nutr. 1996;64(4): 552–558. doi:10.1093/ajcn/64.4.552
17. Solheim TS, Laird BJA, Balstad TR, Bye A, Stene G, Baracos V, Strasser F, Griffiths G, Maddocks M, Fallon M, et al. Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Antiinflammatory medication for Cachexia) trial. BMJ Support Palliat Care. 2018;8(3):258–265. doi:10.1136/ bmjspcare-2017-001440
18. Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer. 2008;44(8):1124–1132. doi:10.1016/j.ejca.2008.02.033
19. Ministry of Education, Culture, Sports, Science and Technology (MEXT). Office for Resources, Policy Division Science and Technology Policy Bureau [Internet]. Standard Tables of Food Composition in Japan Seventh Revised Edition. MEXT; 2015. https:// www.mext.go.jp/en/policy/science_technology/policy/ title01/detail01/1374030.htm [last accessed 2015 Jan 27].
20. Akita H, Takahashi H, Asukai K, Tomokuni A, Wada H, Marukawa S, Yamasaki T, Yanagimoto Y, Takahashi Y, Sugimura K, et al. The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: prospective randomized control study. Clin Nutr Espen. 2019;33: 148–153. doi:10.1016/j.clnesp.2019.06.003
21. Pezzilli R, Caccialanza R, Capurso G, Brunetti O, Milella M, Falconi M. Pancreatic enzyme replacement therapy in pancreatic cancer. Cancers (Basel). 2020; 12(2):275. doi:10.3390/cancers12020275
22. Ueno M, Okusaka T, Omuro Y, Isayama H, Fukutomi A, Ikeda M, Mizuno N, Fukuzawa K, Furukawa M, Iguchi H, et al. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancerdagger. Ann Oncol. 2016;27(3):502–508. doi:10.1093/annonc/mdv603